ORIGINAL ARTICLE   

Journal of Neurosurgical Sciences 2020 February;64(1):37-43

DOI: 10.23736/S0390-5616.16.03745-0

Copyright © 2016 EDIZIONI MINERVA MEDICA

lingua: Inglese

LINAC-based radiosurgery for melanoma, sarcoma and renal cell carcinoma brain metastases

Ernesto MARANZANO ¹ ✉, Michelina CASALE ¹, Rossella RISPOLI ^{1, 2}, Fabio TRIPPA ¹, Lorena DRAGHINI ¹, Fabio ARCIDIACONO ¹, Sandro CARLETTI ^{1, 2}, Paola ANSELMO ¹

¹ Radiotherapy Oncology Center, S. Maria Hospital, Terni, Italy; ² Neurosurgery Center, S. Maria Hospital, Terni, Italy

BACKGROUND: The aim of this study was to report response, overall survival (OS) and toxicity in patients with radioresistant brain metastases (BM) treated with stereotactic radiosurgery (SRS).
METHODS: Patients with renal cell carcinoma, melanoma and sarcoma with one to four brain metastases received SRS without whole brain radiotherapy.
RESULTS: Fifty patients with 77 BM were treated. 46 (92%) patients with 71 BM were evaluable. Median follow-up was 67 months and median OS 11.8 months. At the time of analysis all patients had died. Brain control was conditioned by response to SRS (P<0.0001), while OS by histology (renal cell carcinoma versus melanoma and sarcoma) (P=0.04) and status of the tumour outside the brain (P=0.05). Treatment was well tolerated without more than grade 2 acute toxicity.
CONCLUSIONS: Treatment of BM from radioresistant tumors with SRS assures good brain control and OS with low toxicity. Our data suggest a better prognosis associated to renal cell carcinoma histology.

KEY WORDS: Neoplasm metastasis; Brain; Radiosurgery